October 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Roll Call			Present: Dr. Swee, Dr. Gooen, Dr. Woodward, Dr. Marcus, Ms, Rodriquez, Mr. Schafer, Dr. Barberio, Dr. Moore, Dr. Condoluci, Dr. Lichtbroun, Dr. Gochfeld, Ms. Olson
			Absent: Dr. Moynihan
Review of Minutes	Pages 3-6; Tab 1	Approved	Minutes from the June 2007 meeting were approved.
Secretary's Report	Page 7-8; Tab 2		Recommendations from the April and June 2007 meetings have been implemented. The recommendations included extending coverage to OTC ophthalmic antihistamines, Hepatitis C therapy protocol, and ESA protocol.
Business			
A. Smoking Cessation Protocol	Pages 9-12; Tab 3	Approved	The Board approved the proposed smoking cessation protocol. This will extend coverage of available generic over-the-counter smoking cessation aids in addition to currently available prescription pharmaceuticals.
B. Maraviroc (Selzentry™) Protocol	Pages 13-36; Tab 4	Approved	The proposed protocol for approval of maraviroc was approved by the Board.
Informational Highligh	ts		
Disease Management Update	Pages 37-44; Tab 5		Margaret Springer gave an update to the Board pertaining to the prescribing practices of behavioral health providers and outreach being conducted by the State through educational interventions and peer consultations.
Report on Methadone Dosing	Supplemental Handout		The State presented profiles of clients receiving high doses of methadone which were considered by the Unisys MEP staff to be outliers. The Board recommended that the State take appropriate action if needed. The State has forwarded this information to the Bureau of Program Integrity for further review and investigation.
DUR and MEP Information to	Pages 45-46; Tab 6		MEP provided a description of the different drug utilization edits with information for pharmacists on how to best resolve these issues.

October 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes
Pharmacies			
Unisys Reports	Pages 47-48; Tab 7		Unisys MEP will present updated Unisys denial reports for the Board with complete information.
Most Frequently Utilized Drugs (previous Top 200)	Pages 49-60; Tab 8		The reports are now being processed through the program with the appropriate First Data Bank indicator of specific therapeutic class. This indicator appropriately groups classes of drugs and eliminates any erroneous groupings.
Proposed Meeting Dates	Pages 61-62; Tab 9		The meetings for 2008 are set to occur on January 16, April 16, June 18, and October 15.
Action Items			
1. Provigil Utilization			1. The Board created a sub-committee to address Provigil utilization. The committee will present their findings to the Board at future meetings.
2. Summary of Medicaid Population			2. Description of the different Medicaid populations will be provided at each meeting as a reference.
3. Prescriptions filled for FFS Medicaid			3. The State will trend the number of prescriptions (new and refills) filled per member per month for the FFS Medicaid population.
4. Annual Report			4. The Annual Reports for SFY 2005 to 2006 and SFY 2006 to 2007 have been drafted.
5. Smoking Cessation Protocol			5. The State will present the Smoking Cessation Protocol with information pertaining to the possibility of coverage of these products for adolescents.
6. Disease Management			6. Update will be provided for the CNS project.

October 2007 DURB Meeting Summary

Issue	Attachment*	Action	Notes